Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GnRH Agonist and Intrauterine Insemination

This study has been completed.
Information provided by (Responsible Party):
Jose Bellver, Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier:
First received: July 17, 2007
Last updated: September 5, 2016
Last verified: September 2016
The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Condition Intervention Phase
Intrauterine Insemination
Drug: Tryptorelin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:

Study Start Date: February 2005
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women < 38 years old
  • Bilateral tubal patency confirmed by hysterosonography
  • Normal ultrasound scan of uterus and ovaries
  • Normal day 3 basal hormones
  • Motile sperm count after capacitation ≥ 3 mill/ml

Exclusion Criteria:

  • Endometriosis
  • Polycystic ovary syndrome
  • Uterine disease (polyps, myomas and müllerian diseases)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00503217

Instituto Valenciano de Infertilidad Spain
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
Principal Investigator: Jose Bellver, MD Instituto Valenciano de la Infertilidad
Principal Investigator: Elena Labarta, MD Instituto Valenciano de Infertilidad
  More Information

Responsible Party: Jose Bellver, Gynecologist IVI Valencia, Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier: NCT00503217     History of Changes
Other Study ID Numbers: VLC-JB-0205-307-9 
Study First Received: July 17, 2007
Last Updated: September 5, 2016
Health Authority: Spain: Ministry of Health

Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
intrauterine insemination
GnRH agonist

Additional relevant MeSH terms:
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016